{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:25:43Z","timestamp":1794306343408,"version":"4.9.0"},"reference-count":67,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1001\/jamaoncol.2021.0586","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T14:18:45Z","timestamp":1622729925000},"page":"1383","source":"Crossref","is-referenced-by-count":64,"title":["Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome"],"prefix":"10.1001","volume":"7","author":[{"given":"Jack","family":"Khouri","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"crv210003r1","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","article-title":"The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"issue":"7","key":"crv210003r2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ajh.25495","article-title":"POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management.","volume":"94","author":"Dispenzieri","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"crv210003r3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jnnp-2011-301706","article-title":"Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy.","volume":"83","author":"Nasu","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"crv210003r4","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/(ISSN)1097-4598","article-title":"Overproduction of vascular endothelial growth factor\/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome.","volume":"21","author":"Watanabe","year":"1998","journal-title":"Muscle Nerve"},{"issue":"1","key":"crv210003r5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0953-6205(01)00199-6","article-title":"Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome.","volume":"13","author":"Koga","year":"2002","journal-title":"Eur J Intern Med"},{"issue":"2","key":"crv210003r6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-012-1583-2","article-title":"Multiple angiogenetic factors are upregulated in POEMS syndrome.","volume":"92","author":"Yamada","year":"2013","journal-title":"Ann Hematol"},{"issue":"4","key":"crv210003r7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood.V87.4.1458.bloodjournal8741458","article-title":"Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome.","volume":"87","author":"Gherardi","year":"1996","journal-title":"Blood"},{"key":"crv210003r8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.leukres.2016.09.017","article-title":"Remarkable expression of vascular endothelial growth factor in bone marrow plasma cells of patients with POEMS syndrome.","volume":"50","author":"Wang","year":"2016","journal-title":"Leuk Res"},{"issue":"1","key":"crv210003r9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.hoc.2017.09.011","article-title":"POEMS syndrome: therapeutic options.","volume":"32","author":"Jaccard","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"crv210003r10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009157","article-title":"Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.","volume":"5","author":"Misawa","year":"2015","journal-title":"BMJ Open"},{"issue":"6","key":"crv210003r11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.56.6.807","article-title":"Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMS syndrome.","volume":"56","author":"Michizono","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"crv210003r12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor.","volume":"40","author":"Soubrier","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"6","key":"crv210003r13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1212\/WNL.0b013e318263c42b","article-title":"Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome.","volume":"79","author":"Kanai","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"crv210003r14","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones.","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"issue":"20","key":"crv210003r15","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/blood.2019004197","article-title":"Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome.","volume":"135","author":"Bender","year":"2020","journal-title":"Blood"},{"issue":"1","key":"crv210003r16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/bjh.v190.1","article-title":"Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome.","volume":"190","author":"Kourelis","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"crv210003r17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/bjh.v190.1","article-title":"Mass cytometry in POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) syndrome: looking for a needle in a haystack.","volume":"190","author":"Caers","year":"2020","journal-title":"Br J Haematol"},{"key":"crv210003r18","first-page":"19","article-title":"A highly heterogeneous mutational pattern in POEMS syndrome.","volume":"136","author":"Chen","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"crv210003r19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.hoc.2017.09.012","article-title":"The peripheral neuropathies of POEMS syndrome and Castleman disease.","volume":"32","author":"Mauermann","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"crv210003r20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/jnnp.2007.135681","article-title":"Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome.","volume":"79","author":"Koike","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"crv210003r21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/WCO.0000000000000610","article-title":"POEMS syndrome.","volume":"31","author":"Keddie","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"crv210003r22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.34.6.712","article-title":"The Crow-Fukase syndrome: a study of 102 cases in Japan.","volume":"34","author":"Nakanishi","year":"1984","journal-title":"Neurology"},{"issue":"1","key":"crv210003r23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.hoc.2017.09.010","article-title":"POEMS syndrome: diagnosis and investigative work-up.","volume":"32","author":"Dispenzieri","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"crv210003r24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.4065\/82.7.836","article-title":"Endocrinopathy in POEMS syndrome: the Mayo Clinic experience.","volume":"82","author":"Gandhi","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"crv210003r25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/ijd.2013.52.issue-11","article-title":"Cutaneous manifestations in patients with POEMS syndrome.","volume":"52","author":"Miest","year":"2013","journal-title":"Int J Dermatol"},{"issue":"4","key":"crv210003r26","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ophtha.2010.08.013","article-title":"Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome.","volume":"118","author":"Kaushik","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"crv210003r27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ajh.21707","article-title":"Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.","volume":"85","author":"Stankowski-Drengler","year":"2010","journal-title":"Am J Hematol"},{"issue":"7","key":"crv210003r28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00277-014-2019-y","article-title":"Serum immunoglobulin free light chain and heavy\/light chain measurements in POEMS syndrome.","volume":"93","author":"Wang","year":"2014","journal-title":"Ann Hematol"},{"issue":"24","key":"crv210003r29","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1182\/blood-2010-11-316935","article-title":"Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients.","volume":"117","author":"Dao","year":"2011","journal-title":"Blood"},{"issue":"7","key":"crv210003r30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00277-010-1149-0","article-title":"Clinical characteristics and long-term outcome of patients with POEMS syndrome in China.","volume":"90","author":"Li","year":"2011","journal-title":"Ann Hematol"},{"issue":"12","key":"crv210003r31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.2169\/internalmedicine.42.1240","article-title":"Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome.","volume":"42","author":"Tokashiki","year":"2003","journal-title":"Intern Med"},{"issue":"5","key":"crv210003r32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000486","article-title":"Raised VEGF: high sensitivity and specificity in the diagnosis of POEMS syndrome.","volume":"5","author":"Pihan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"crv210003r33","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/bloodadvances.2020001492","article-title":"High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry.","volume":"4","author":"Sayar","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"crv210003r34","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/WNL.0b013e3181bd136b","article-title":"Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics.","volume":"73","author":"Dupont","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"crv210003r35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3324\/haematol.2012.073031","article-title":"Pulmonary hypertension in POEMS syndrome.","volume":"98","author":"Li","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"crv210003r36","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/echo.v36.11","article-title":"Evaluating heart function in patients with POEMS syndrome.","volume":"36","author":"He","year":"2019","journal-title":"Echocardiography"},{"issue":"2","key":"crv210003r37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejrad.2009.06.004","article-title":"18F-FDG PET\/CT in the evaluation of POEMS syndrome.","volume":"76","author":"Albert\u00ed","year":"2010","journal-title":"Eur J Radiol"},{"issue":"6","key":"crv210003r38","article-title":"Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.","author":"Kuwabara","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"crv210003r39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ajh.v91.6","article-title":"Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience.","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"crv210003r40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/leu.2015.344","article-title":"Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.","volume":"30","author":"Kourelis","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"crv210003r41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2013-03-487025","article-title":"Outcomes of patients with POEMS syndrome treated initially with radiation.","volume":"122","author":"Humeniuk","year":"2013","journal-title":"Blood"},{"key":"crv210003r42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13014-014-0265-8","article-title":"The role of radiotherapy in the management of POEMS syndrome.","volume":"9","author":"Suh","year":"2014","journal-title":"Radiat Oncol"},{"issue":"1","key":"crv210003r43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","article-title":"Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience.","volume":"120","author":"D\u2019Souza","year":"2012","journal-title":"Blood"},{"issue":"1","key":"crv210003r44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3324\/haematol.2016.148460","article-title":"High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation.","volume":"102","author":"Cook","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"crv210003r45","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.bbmt.2018.01.026","article-title":"Efficacy and long-term outcomes of autologous stem cell transplantation in POEMS Syndrome: a nationwide survey in Japan.","volume":"24","author":"Kawajiri-Manako","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"crv210003r46","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1111\/bjh.v186.6","article-title":"High-dose therapy and autologous transplantation for POEMS syndrome: effective, but how to optimise?","volume":"186","author":"Tomkins","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"crv210003r47","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1182\/blood.V99.8.3057","article-title":"High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome.","volume":"99","author":"Jaccard","year":"2002","journal-title":"Blood"},{"issue":"5","key":"crv210003r48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","article-title":"Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.","volume":"80","author":"Dispenzieri","year":"2008","journal-title":"Eur J Haematol"},{"issue":"1","key":"crv210003r49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5045\/br.2014.49.1.42","article-title":"Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience.","volume":"49","author":"Jang","year":"2014","journal-title":"Blood Res"},{"issue":"6","key":"crv210003r50","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/leu.2017.27","article-title":"Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome.","volume":"31","author":"Li","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"crv210003r51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bbmt.2016.10.024","article-title":"Safety and efficacy of granulocyte colony-stimulating factor monotherapy for peripheral blood stem cell collection in POEMS syndrome.","volume":"23","author":"Muto","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"crv210003r52","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.bbmt.2019.08.011","article-title":"Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at 2 hematologic Italian centers.","volume":"25","author":"Autore","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"crv210003r53","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.2017.179.issue-5","article-title":"Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.","volume":"179","author":"Nozza","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"crv210003r54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/ajh.v88.3","article-title":"Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.","volume":"88","author":"Royer","year":"2013","journal-title":"Am J Hematol"},{"issue":"11","key":"crv210003r55","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(16)30176-4","article-title":"Thalidomide and POEMS syndrome: a cautious step forward.","volume":"15","author":"Jaccard","year":"2016","journal-title":"Lancet Neurol"},{"issue":"9","key":"crv210003r56","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3109\/10428194.2013.869329","article-title":"Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.","volume":"55","author":"Zagouri","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"crv210003r57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajh.v93.6","article-title":"A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.","volume":"93","author":"Li","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"crv210003r58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bjh.2018.181.issue-1","article-title":"Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen.","volume":"181","author":"He","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"crv210003r59","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/ejh.2012.88.issue-6","article-title":"Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.","volume":"88","author":"Warsame","year":"2012","journal-title":"Eur J Haematol"},{"key":"crv210003r60","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1182\/blood-2019-127366","article-title":"A prospective pilot study of ixazomib, lenalidomide, and dexamethasone for patients with newly diagnosed or relapsed\/refractory POEMS syndrome.","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"4","key":"crv210003r61","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-019-0391-2","article-title":"What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?","volume":"33","author":"Zhao","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"crv210003r62","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.mayocp.2018.02.001","article-title":"Daratumumab for POEMS syndrome.","volume":"93","author":"Khan","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"crv210003r63","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000381","article-title":"Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome.","volume":"4","author":"Gavriatopoulou","year":"2020","journal-title":"Hemasphere"},{"issue":"12","key":"crv210003r65","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1136\/jnnp-2012-304874","article-title":"Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome.","volume":"84","author":"Sekiguchi","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"crv210003r66","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1182\/blood-2005-12-5045","article-title":"Bevacizumab therapy for POEMS syndrome.","volume":"107","author":"Straume","year":"2006","journal-title":"Blood"},{"issue":"3","key":"crv210003r67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher"},{"key":"crv210003r64","unstructured":"A phase II trial for the treatment of poems syndrome with daratumumab. ClinicalTrials.gov identifier NCT04396496. Updated March 2, 2021. Accessed September 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04396496"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2780474\/jamaoncology_khouri_2021_rv_210003_1631288502.08192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T09:30:01Z","timestamp":1699090201000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2780474"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.0586","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}